GleamWall
中文EN

TRAW Traws Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1130598 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,159.3%
TTM net income YoY90.5%
TTM EPS YoY95.1%
Revenue 3-yr CAGR132.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-554.6%
Net margin-467.6%
FCF margin—
EBITDA margin-554.0%

Returns

ROE-1,059.6%
ROA-124.5%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets63.5%
Debt / equity0.00x
Current ratio1.22x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.46x
Accruals ratio57.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312024Q4*2025-12-312025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$2.73M$57,000$56,000
R&D expense$1.83M$2.29M$4.91M$5.04M$2.31M$2.29M$2.51M$1.86M
SG&A expense$1.77M$3.48M$2.03M$2.33M$1.74M$1.69M$2.75M$3.48M
Operating income-$3.60M-$4.37M-$6.95M-$7.37M-$4.05M-$1.25M-$5.20M-$5.28M
Net income-$3.55M-$4.21M-$7.11M-$7.44M-$3.96M-$915,000$21.49M-$29.92M
EBITDA-$3.56M-$4.32M-$6.90M-$7.32M-$4.04M-$1.25M-$5.20M-$5.28M
EPS (basic)-0.18-0.23-0.53—-0.34-0.112.17—
EPS (diluted)-0.18-0.23-0.53—-0.34-0.112.09—
Weighted avg. shares (diluted)17.04M15.86M10.64M—8.82M5.82M7.22M—
Balance sheet
Cash & equivalents$2.34M$5.02M$3.13M$3.82M$6.42M$13.08M$15.94M$21.34M
Receivables$2.19M$2.30M$1.69M$3.79M$1.99M$1.32M$1.65M$1.76M
Current assets$4.98M$7.87M$5.67M$7.98M$9.62M$15.37M$18.86M$24.95M
PP&E, net$5,000$5,000$6,000$7,000$7,000$8,000$9,000$10,000
Intangibles$2.40M$2.44M$2.48M$2.53M$2.57M———
Total assets$7.52M$10.31M$8.16M$10.62M$12.44M$15.62M$19.06M$24.96M
Current liabilities$9.64M$9.73M$13.21M$11.15M$7.89M$7.35M$10.40M$11.53M
Total liabilities$9.65M$9.78M$13.47M$11.25M$7.90M$7.36M$13.06M$56.59M
Shareholders' equity-$2.13M$535,000-$5.31M-$629,000$4.54M$8.26M$6.00M-$31.63M
Shares outstanding15.38M15.26M10.16M9.07M7.13M7.07M5.08M3.65M
Cash flow statement
Operating cash flow-$2.48M-$7.50M-$2.58M-$2.76M-$4.01M-$5.98M-$5.44M-$4.04M
Capital expenditure———$0———$0
Free cash flow———-$2.76M———-$4.04M
Investing cash flow———$0———$0
Financing cash flow-$197,000$9.39M$1.90M$158,000-$62,000$3.10M$13,000$19.98M
Depreciation & amortization$43,000$44,000$44,000$44,000$15,000$1,000$1,000$2,000
Stock-based compensation$795,000$816,000$634,000$327,000$135,000$105,000$161,000$334,000

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.